Breaking News

Today
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Hot Stocks
Eli Lilly, Incyte announce BRAVE-AA2 study met primary endpoint » 06:51
03/03/21
03/03
06:51
03/03/21
06:51
LLY

Eli Lilly

$204.13 /

-2.26 (-1.10%)

, INCY

Incyte

$78.57 /

-1.12 (-1.41%)

Eli Lilly (LLY) and…

Eli Lilly (LLY) and Incyte (INCY) announced top-line results from BRAVE-AA2, a Phase 3 study evaluating the efficacy and safety of once-daily baricitinib 2-mg and 4-mg in adults with severe alopecia areata, or AA. Both doses of baricitinib met the primary efficacy endpoint at Week 36, demonstrating a statistically significant improvement in scalp hair regrowth compared to those randomized to placebo. AA is an autoimmune disease that causes patchy hair loss on the scalp, face and sometimes on other areas of the body that can progress. Baricitinib has received breakthrough therapy designation from the FDA for the treatment of AA. This classification aims to expedite the development and review of drugs that are intended to treat a serious condition when preliminary clinical evidence indicates that the drug may demonstrate substantial improvement over already available therapies on a clinically significant endpoint. There are currently no FDA-approved treatments for AA. This multicenter, randomized, double-blind, placebo-controlled study included 546 adults with a Severity of Alopecia Tool, or SALT, score of 50 and a current episode of severe AA lasting at least six months but no more than eight years. The study included a diverse patient population from Argentina, Australia, Brazil, China, Israel, Japan, South Korea, Taiwan and the U.S. Safety outcomes of baricitinib in BRAVE-AA2 were consistent with its established safety profile in patients with rheumatoid arthritis, or RA, and atopic dermatitis, or AD. No deaths, major adverse cardiovascular events, or MACE, or venous thromboembolic events, or VTEs, were reported in the study. BRAVE-AA2 is the first Phase 3 study with "positive" results in patients with AA. Data from an additional Phase 3 study of baricitinib in AA will be available in the first half of this year. Detailed results from the BRAVE program will be presented at an upcoming medical conference and published in a peer-reviewed journal later this year. AA is the second potential treatment indication in dermatology for baricitinib after AD. Baricitinib is an oral JAK inhibitor discovered by Incyte and licensed to Lilly. It is approved and commercially available as Olumiant in the U.S. and more than 70 countries as a treatment for adults with moderate to severe active RA and in the European Union and Japan for the treatment of adult patients with moderate to severe AD who are candidates for systemic therapy. Baricitinib is also being investigated in systematic lupus erythematosus, juvenile idiopathic arthritis and COVID-19.

ShowHide Related Items >><<
LLY Eli Lilly
$204.13 /

-2.26 (-1.10%)

INCY Incyte
$78.57 /

-1.12 (-1.41%)

LLY Eli Lilly
$204.13 /

-2.26 (-1.10%)

03/02/21 JPMorgan
Eli Lilly risk/reward favorable into Alzheimer's data, says JPMorgan
02/18/21 H.C. Wainwright
Rigel Pharmaceuticals price target raised to $11 from $8 at H.C. Wainwright
02/18/21 Piper Sandler
Rigel share setup 'distinctly positive' after Lilly deal, says Piper Sandler
02/12/21 Cowen
Eli Lilly price target raised to $235 from $195 at Cowen
INCY Incyte
$78.57 /

-1.12 (-1.41%)

02/10/21 SVB Leerink
Incyte downgraded to Market Perform from Outperform at SVB Leerink
01/07/21 Truist
Incyte initiated with a Buy at Truist
01/07/21 Truist
Incyte initiated with a Buy at Truist
01/04/21 Guggenheim
Incyte upgraded to Buy from Neutral at Guggenheim
LLY Eli Lilly
$204.13 /

-2.26 (-1.10%)

INCY Incyte
$78.57 /

-1.12 (-1.41%)

LLY Eli Lilly
$204.13 /

-2.26 (-1.10%)

LLY Eli Lilly
$204.13 /

-2.26 (-1.10%)

INCY Incyte
$78.57 /

-1.12 (-1.41%)

LLY Eli Lilly
$204.13 /

-2.26 (-1.10%)

INCY Incyte
$78.57 /

-1.12 (-1.41%)

Yesterday
Conference/Events
Mizuho healthcare analysts to hold an analyst/industry conference call » 13:01
03/02/21
03/02
13:01
03/02/21
13:01
LLY

Eli Lilly

$207.50 /

+1.11 (+0.54%)

Analysts discuss Eli…

Analysts discuss Eli Lilly's Alzheimer's Disease Drug, Donanemab and the real-world clnical implications with Paul R. Solomon, PhD on an Analyst/Industry conference call to be held on March 5.

ShowHide Related Items >><<
LLY Eli Lilly
$207.50 /

+1.11 (+0.54%)

LLY Eli Lilly
$207.50 /

+1.11 (+0.54%)

03/02/21 JPMorgan
Eli Lilly risk/reward favorable into Alzheimer's data, says JPMorgan
02/18/21 H.C. Wainwright
Rigel Pharmaceuticals price target raised to $11 from $8 at H.C. Wainwright
02/18/21 Piper Sandler
Rigel share setup 'distinctly positive' after Lilly deal, says Piper Sandler
02/12/21 Cowen
Eli Lilly price target raised to $235 from $195 at Cowen
LLY Eli Lilly
$207.50 /

+1.11 (+0.54%)

LLY Eli Lilly
$207.50 /

+1.11 (+0.54%)

LLY Eli Lilly
$207.50 /

+1.11 (+0.54%)

LLY Eli Lilly
$207.50 /

+1.11 (+0.54%)

Recommendations
Eli Lilly risk/reward favorable into Alzheimer's data, says JPMorgan » 07:01
03/02/21
03/02
07:01
03/02/21
07:01
LLY

Eli Lilly

$206.39 /

+1.45 (+0.71%)

JPMorgan analyst Chris…

JPMorgan analyst Chris Schott sees a positive risk/reward on Eli Lilly into the Phase 2 donanemab data presentation for the TRAILBLAZER-ALZ study with shares potentially up 5%-10% assuming results that suggest a high probability of eventual approval for the drug. This would include statistical significance on CDR-SB coupled with plaque reduction and Alzheimer's disease progression model data suggesting "clear and rapid efficacy of the drug," Schott tells investors in a research note. The analyst sees this outcome as a high probability event based on Eli Lilly's commentary and keeps an Overweight rating on the shares with a $240 price target.

ShowHide Related Items >><<
LLY Eli Lilly
$206.39 /

+1.45 (+0.71%)

LLY Eli Lilly
$206.39 /

+1.45 (+0.71%)

02/18/21 H.C. Wainwright
Rigel Pharmaceuticals price target raised to $11 from $8 at H.C. Wainwright
02/18/21 Piper Sandler
Rigel share setup 'distinctly positive' after Lilly deal, says Piper Sandler
02/12/21 Cowen
Eli Lilly price target raised to $235 from $195 at Cowen
02/08/21 SVB Leerink
AbCellera price target raised to $52 from $45 at SVB Leerink
LLY Eli Lilly
$206.39 /

+1.45 (+0.71%)

LLY Eli Lilly
$206.39 /

+1.45 (+0.71%)

LLY Eli Lilly
$206.39 /

+1.45 (+0.71%)

LLY Eli Lilly
$206.39 /

+1.45 (+0.71%)

Monday
Conference/Events
Cantor Fitzgerald biopharma analysts hold an analyst/industry conference call » 15:48
03/01/21
03/01
15:48
03/01/21
15:48
ADVM

Adverum Biotechnologies

$13.31 /

+0.455 (+3.54%)

, UBX

Unity Biotechnology

$7.53 /

+0.7 (+10.25%)

, AGTC

Applied Genetic

$5.64 /

+0.54 (+10.59%)

, JNJ

Johnson & Johnson

$159.50 /

+1.08 (+0.68%)

, MGTX

MeiraGTx

$15.21 /

+0.4 (+2.70%)

, NITE

Nightstar Therapeutics

$25.41 /

+ (+0.00%)

, BIIB

Biogen

$272.79 /

-0.16 (-0.06%)

, AERI

Aerie Pharmaceuticals

$19.36 /

+0.96 (+5.22%)

, ALDX

Aldeyra

$12.20 /

-0.05 (-0.41%)

Biopharmaceuticals…

Biopharmaceuticals Analyst Chen, along with Dr. Ruchita Amin, Retina Specialist at Retina Vitreous Associates and Dr. Roger Goldberg, Partner and Vitreoretinal Surgeon at Bay Area Retina Associates, discuss hot topics and key 2021 focus areas in eye diseases on an Analyst/Industry Conference Call to be held on March 8 at 1 pm.

ShowHide Related Items >><<
UBX Unity Biotechnology
$7.53 /

+0.7 (+10.25%)

MGTX MeiraGTx
$15.21 /

+0.4 (+2.70%)

JNJ Johnson & Johnson
$159.50 /

+1.08 (+0.68%)

BIIB Biogen
$272.79 /

-0.16 (-0.06%)

ALDX Aldeyra
$12.20 /

-0.05 (-0.41%)

AGTC Applied Genetic
$5.64 /

+0.54 (+10.59%)

AERI Aerie Pharmaceuticals
$19.36 /

+0.96 (+5.22%)

ADVM Adverum Biotechnologies
$13.31 /

+0.455 (+3.54%)

ADVM Adverum Biotechnologies
$13.31 /

+0.455 (+3.54%)

12/15/20 UBS
Adverum Biotechnologies initiated with a Neutral at UBS
11/15/20 Piper Sandler
Adverum Biotechnologies shares should grind higher over time, says Piper Sandler
11/12/20 Raymond James
Adverum Biotechnologies upgraded to Market Perform from Underperform at Raymond James
11/12/20 Raymond James
Adverum Biotechnologies upgraded to Market Perform at Raymond James
UBX Unity Biotechnology
$7.53 /

+0.7 (+10.25%)

02/16/21 Citi
Unity Biotechnology downgraded to Sell from Neutral at Citi
08/18/20
Fly Intel: Top five analyst downgrades
08/18/20 Morgan Stanley
Unity Biotechnology downgraded at Morgan Stanley as UBX101 doesn't meet endpoint
08/18/20 Citi
Unity Biotechnology downgraded to Neutral from Buy at Citi
AGTC Applied Genetic
$5.64 /

+0.54 (+10.59%)

02/02/21 H.C. Wainwright
Applied Genetic price target raised to $24 from $18 at H.C. Wainwright
02/01/21 Roth Capital
Applied Genetic price target raised to $35 from $30 at Roth Capital
11/17/20 Roth Capital
Applied Genetic price target raised to $30 from $26 at Roth Capital
11/11/20 H.C. Wainwright
Applied Genetic XLRP data 'continue to impress,' says H.C. Wainwright
JNJ Johnson & Johnson
$159.50 /

+1.08 (+0.68%)

02/10/21 BTIG
Model N upgraded to Buy from Neutral at BTIG
02/01/21 SVB Leerink
Moderna price target raised to $80 from $69 at SVB Leerink
02/01/21 Wells Fargo
Moderna price target raised to $145 from $129 at Wells Fargo
02/01/21 BofA
BofA downgrades Moderna to Underperform, sees shares priced for 'best-case'
MGTX MeiraGTx
$15.21 /

+0.4 (+2.70%)

02/16/21 Chardan
MeiraGTx called a Top Pick for 2021 at Chardan
12/17/20 Chardan
Chardan boosts MeiraGTx target to $55, say buy shares 'now'
12/17/20 Piper Sandler
Piper says MeiraGTx not getting credit for RIX gene therapy that 'clearly works'
10/22/20 RBC Capital
MeiraGTx initiated with an Outperform at RBC Capital
NITE Nightstar Therapeutics
$25.41 /

+ (+0.00%)

BIIB Biogen
$272.79 /

-0.16 (-0.06%)

02/17/21 Cantor Fitzgerald
Biogen price target lowered to $268 from $278 at Cantor Fitzgerald
02/08/21 Citi
Expert sees Biogen aducanumab approval 50/50 at best, says Citi
02/04/21 SVB Leerink
Biogen price target lowered to $380 from $430 at SVB Leerink
02/04/21 Credit Suisse
Biogen price target lowered to $338 from $350 at Credit Suisse
AERI Aerie Pharmaceuticals
$19.36 /

+0.96 (+5.22%)

11/09/20 H.C. Wainwright
Aerie Pharmaceuticals price target lowered to $29 from $31 at H.C. Wainwright
10/28/20 H.C. Wainwright
Aerie Pharmaceuticals $50M upfront should reduce overhang, says H.C. Wainwright
10/19/20 BofA
Aerie Pharmaceuticals downgraded to Underperform from Neutral at BofA
10/19/20 BofA
Aerie Pharmaceuticals downgraded to Underperform from Neutral at BofA
ALDX Aldeyra
$12.20 /

-0.05 (-0.41%)

02/08/21 H.C. Wainwright
Aldeyra initiated with a Buy at H.C. Wainwright
01/28/21 JonesTrading
Aldeyra assumed with a Buy at JonesTrading
01/08/21 Jefferies
Aldeyra could double if topline of TRANQUILITY study positive, says Jefferies
01/08/21 Citi
Aldeyra shares have 'plenty of upside' despite 26% rally, says Citi
UBX Unity Biotechnology
$7.53 /

+0.7 (+10.25%)

MGTX MeiraGTx
$15.21 /

+0.4 (+2.70%)

JNJ Johnson & Johnson
$159.50 /

+1.08 (+0.68%)

BIIB Biogen
$272.79 /

-0.16 (-0.06%)

ALDX Aldeyra
$12.20 /

-0.05 (-0.41%)

AGTC Applied Genetic
$5.64 /

+0.54 (+10.59%)

AERI Aerie Pharmaceuticals
$19.36 /

+0.96 (+5.22%)

ADVM Adverum Biotechnologies
$13.31 /

+0.455 (+3.54%)

  • 28
    Jan
  • 14
    Jan
  • 19
    Nov
  • 13
    Aug
JNJ Johnson & Johnson
$159.50 /

+1.08 (+0.68%)

BIIB Biogen
$272.79 /

-0.16 (-0.06%)

UBX Unity Biotechnology
$7.53 /

+0.7 (+10.25%)

JNJ Johnson & Johnson
$159.50 /

+1.08 (+0.68%)

BIIB Biogen
$272.79 /

-0.16 (-0.06%)

ALDX Aldeyra
$12.20 /

-0.05 (-0.41%)

AGTC Applied Genetic
$5.64 /

+0.54 (+10.59%)

AERI Aerie Pharmaceuticals
$19.36 /

+0.96 (+5.22%)

BIIB Biogen
$272.79 /

-0.16 (-0.06%)

JNJ Johnson & Johnson
$159.50 /

+1.08 (+0.68%)

BIIB Biogen
$272.79 /

-0.16 (-0.06%)

Conference/Events
Cowen to hold a virtual conference » 09:07
03/01/21
03/01
09:07
03/01/21
09:07
QGEN

Qiagen

$50.02 /

-0.33 (-0.66%)

, SLN

Silence Therapeutics

$28.01 /

+ (+0.00%)

, BIIB

Biogen

$272.68 /

-4.95 (-1.78%)

, AXSM

Axsome Therapeutics

$67.52 /

-1.04 (-1.52%)

, GBT

Global Blood Therapeutics

$42.60 /

-0.885 (-2.04%)

, OCUL

Ocular Therapeutix

$18.40 /

+0.27 (+1.49%)

, ACAD

Acadia

$49.00 /

+1.605 (+3.39%)

, PACB

Pacific Biosciences

$30.57 /

-0.59 (-1.89%)

, ZTS

Zoetis

$155.41 /

-1.14 (-0.73%)

, QTNT

Quotient

$4.49 /

-0.06 (-1.32%)

, DVAX

Dynavax

$8.75 /

+0.595 (+7.30%)

, OTRK

Ontrak

$59.13 /

-3.3 (-5.29%)

, ARQT

Arcutis Biotherapeutics

$34.11 /

+0.01 (+0.03%)

, PFE

Pfizer

$33.49 /

-0.335 (-0.99%)

, BLFS

BioLife Solutions

$39.29 /

+0.07 (+0.18%)

, CHRS

Coherus Biosciences

$16.22 /

+0.97 (+6.36%)

, SAGE

Sage Therapeutics

$85.02 /

+1.45 (+1.74%)

, CERS

Cerus

$6.14 /

-0.325 (-5.03%)

, EXEL

Exelixis

$21.70 /

-0.26 (-1.18%)

, ALNY

Alnylam

$147.94 /

+1.4 (+0.96%)

41st Annual Healthcare…

41st Annual Healthcare Virtual Conference will be held on March 1-4 beginning at 9:10 am on March 1. Webcast Link

ShowHide Related Items >><<
ZTS Zoetis
$155.41 /

-1.14 (-0.73%)

SLN Silence Therapeutics
$28.01 /

+ (+0.00%)

SAGE Sage Therapeutics
$85.02 /

+1.45 (+1.74%)

QTNT Quotient
$4.49 /

-0.06 (-1.32%)

QGEN Qiagen
$50.02 /

-0.33 (-0.66%)

PFE Pfizer
$33.49 /

-0.335 (-0.99%)

PACB Pacific Biosciences
$30.57 /

-0.59 (-1.89%)

OTRK Ontrak
$59.13 /

-3.3 (-5.29%)

OCUL Ocular Therapeutix
$18.40 /

+0.27 (+1.49%)

GBT Global Blood Therapeutics
$42.60 /

-0.885 (-2.04%)

EXEL Exelixis
$21.70 /

-0.26 (-1.18%)

DVAX Dynavax
$8.75 /

+0.595 (+7.30%)

CHRS Coherus Biosciences
$16.22 /

+0.97 (+6.36%)

CERS Cerus
$6.14 /

-0.325 (-5.03%)

BLFS BioLife Solutions
$39.29 /

+0.07 (+0.18%)

BIIB Biogen
$272.68 /

-4.95 (-1.78%)

AXSM Axsome Therapeutics
$67.52 /

-1.04 (-1.52%)

ARQT Arcutis Biotherapeutics
$34.11 /

+0.01 (+0.03%)

ALNY Alnylam
$147.94 /

+1.4 (+0.96%)

QGEN Qiagen
$50.02 /

-0.33 (-0.66%)

02/19/21 Berenberg
Qiagen price target raised to EUR 56 from EUR 52 at Berenberg
02/09/21 William Blair
Quidel, Qiagen merger would not make sense, says William Blair
02/09/21 Wells Fargo
Qiagen shares should be sold on latest merger talk, says Wells Fargo
02/09/21 Citi
Merger with Qiagen would benefit Quidel, says Citi
SLN Silence Therapeutics
$28.01 /

+ (+0.00%)

11/18/20 BTIG
Silence Therapeutics initiated with a Buy at BTIG
BIIB Biogen
$272.68 /

-4.95 (-1.78%)

02/17/21 Cantor Fitzgerald
Biogen price target lowered to $268 from $278 at Cantor Fitzgerald
02/08/21 Citi
Expert sees Biogen aducanumab approval 50/50 at best, says Citi
02/04/21 SVB Leerink
Biogen price target lowered to $380 from $430 at SVB Leerink
02/04/21 Credit Suisse
Biogen price target lowered to $338 from $350 at Credit Suisse
AXSM Axsome Therapeutics
$67.52 /

-1.04 (-1.52%)

01/08/21
Fly Intel: Top five analyst initiations
01/08/21 Jefferies
Axsome Therapeutics initiated with a Buy at Jefferies
12/15/20 Mizuho
Axsome Therapeutics initiated with a Buy at Mizuho
12/03/20 Cantor Fitzgerald
Axsome Therapeutics price target raised to $161 from $131 at Cantor Fitzgerald
GBT Global Blood Therapeutics
$42.60 /

-0.885 (-2.04%)

02/25/21 William Blair
Global Blood Therapeutics downgraded to Market Perform at William Blair
01/27/21 Oppenheimer
Global Blood Therapeutics' MAA accepted ahead of schedule, says Oppenheimer
01/20/21 Piper Sandler
Global Blood downgraded to Neutral from Overweight at Piper Sandler
12/15/20 H.C. Wainwright
Global Blood Therapeutics assumed with a Buy at H.C. Wainwright
OCUL Ocular Therapeutix
$18.40 /

+0.27 (+1.49%)

02/12/21 Piper Sandler
Ocular Therapeutix to update on OTX-TKI's Phase I wAMD, says Piper Sandler
12/30/20 JMP Securities
Ocular Therapeutix price target raised to $30 from $20 at JMP Securities
12/28/20
Fly Intel: Top five analyst calls
12/28/20 H.C. Wainwright
Ocular Therapeutix downgraded to Neutral from Buy at H.C. Wainwright
ACAD Acadia
$49.00 /

+1.605 (+3.39%)

02/25/21 Mizuho
Acadia price target raised to $70 from $69 at Mizuho
12/29/20 Cantor Fitzgerald
Acadia price target raised to $70 from $61 at Cantor Fitzgerald
12/15/20 Mizuho
Acadia initiated with a Buy at Mizuho
11/16/20 Raymond James
Acadia upgraded to Strong Buy from Outperform at Raymond James
PACB Pacific Biosciences
$30.57 /

-0.59 (-1.89%)

02/11/21 Cantor Fitzgerald
Pacific Biosciences price target raised to $62 from $45 at Cantor Fitzgerald
02/11/21 Piper Sandler
Pacific Biosciences upgraded to Overweight from Neutral at Piper Sandler
01/15/21 Piper Sandler
Pacific Biosciences price target raised to $20 from $12 at Piper Sandler
01/12/21 Cantor Fitzgerald
Pacific Biosciences price target raised to $45 from $25 at Cantor Fitzgerald
ZTS Zoetis
$155.41 /

-1.14 (-0.73%)

02/17/21 Credit Suisse
Zoetis price target raised to $203 from $197 at Credit Suisse
11/12/20 Truist
Zoetis price target raised to $170 from $160 at Truist
11/06/20 Barclays
Zoetis price target raised to $189 from $175 at Barclays
09/21/20 Atlantic Equities
Zoetis initiated with an Overweight at Atlantic Equities
QTNT Quotient
$4.49 /

-0.06 (-1.32%)

05/18/20 Cowen
Quotient partner update suggests progress on antibody front, says Cowen
DVAX Dynavax
$8.75 /

+0.595 (+7.30%)

02/08/21 Evercore ISI
Dynavax had 'big vaccine update week,' says Evercore ISI
02/01/21 Cowen
Dynavax undervalued for potential of Heplisav and COVID vaccine, says Cowen
02/01/21 H.C. Wainwright
Dynavax price target raised to $15 from $14 at H.C. Wainwright
11/06/20 H.C. Wainwright
Dynavax price target raised to $14 from $12 at H.C. Wainwright
OTRK Ontrak
$59.13 /

-3.3 (-5.29%)

01/05/21 Benchmark
GM, Roku, Marcus among Benchmark's Best Ideas for first half of 2021
01/04/21 B. Riley Securities
Ontrak price target raised to $110 from $100 at B. Riley Securities
11/18/20 B. Riley Securities
Ontrak initiated with a Buy at B. Riley Securities
10/02/20 Canaccord
Ontrak analysis points to significant upside for shares, says Canaccord
ARQT Arcutis Biotherapeutics
$34.11 /

+0.01 (+0.03%)

02/02/21 Truist
Arcutis Biotherapeutics price target raised to $48 from $38 at Truist
02/01/21 Cowen
Arcutis Biotherapeutics price target raised to $80 from $55 at Cowen
01/28/21 JonesTrading
Arcutis Biotherapeutics initiated with a Buy at JonesTrading
11/09/20 Goldman Sachs
Arcutis Biotherapeutics upgraded to Buy from Neutral at Goldman Sachs
PFE Pfizer
$33.49 /

-0.335 (-0.99%)

02/23/21 B. Riley Securities
B. Riley remains 'aggressive' buyer of Novavax after updated FDA guidance
02/10/21 KeyBanc
Maravai Lifesciences price target raised to $39 from $33 at KeyBanc
02/04/21 DZ Bank
Pfizer upgraded to Buy from Hold at DZ Bank
02/03/21 Mizuho
Pfizer price target lowered to $42 from $44 at Mizuho
BLFS BioLife Solutions
$39.29 /

+0.07 (+0.18%)

12/28/20 Northland
BioLife Solutions price target raised to $55 from $35 at Northland
11/09/20 KeyBanc
BioLife Solutions initiated with an Overweight at KeyBanc
10/19/20 B. Riley Securities
BioLife Solutions price target raised to $35.50 from $30 at B. Riley Securities
09/23/20 B. Riley Securities
BioLife Solutions price target raised to $30 from $25.50 at B. Riley FBR
CHRS Coherus Biosciences
$16.22 /

+0.97 (+6.36%)

02/25/21 Citi
Coherus Biosciences price target lowered to $27 from $30 at Citi
02/25/21 H.C. Wainwright
Coherus Biosciences price target lowered to $29 from $33 at H.C. Wainwright
11/19/20 Mizuho
Coherus Biosciences price target lowered to $30 from $35 at Mizuho
08/21/20 Mizuho
Express Scripts exclusion does not impact Coherus, says Mizuho
SAGE Sage Therapeutics
$85.02 /

+1.45 (+1.74%)

02/26/21 Mizuho
Sage Therapeutics downgraded to Neutral from Buy at Mizuho
02/25/21 Oppenheimer
Sage Therapeutics price target raised to $102 from $90 at Oppenheimer
02/25/21 H.C. Wainwright
Sage Therapeutics price target raised to $86 from $74 at H.C. Wainwright
02/24/21 Stifel
Stifel cuts Sage target to $121, reiterates Buy after quarterly results
CERS Cerus
$6.14 /

-0.325 (-5.03%)

11/30/20 Cowen
Value proposition for Cerus' Intercept cryo 'clear,' says Cowen
10/07/20 BTIG
Cerus assumed with a Buy at BTIG
08/19/20 Stifel
Cerus story about platelets, not convalescent plasma, says Stifel
08/10/20 Cowen
Cerus multi-layered sales growth trajectory 'convincing,' says Cowen
EXEL Exelixis
$21.70 /

-0.26 (-1.18%)

02/15/21 Piper Sandler
Exelixis price target raised to $36 from $33 at Piper Sandler
01/25/21 Piper Sandler
Piper says Exelixis could have 'blockbuster opportunity' with XL102
01/22/21 Piper Sandler
Exelixis combo approval came a month ahead of PDUFA, says Piper Sandler
01/20/21 William Blair
Exelixis selloff on competitive concerns an 'overreaction,' says William Blair
ALNY Alnylam
$147.94 /

+1.4 (+0.96%)

02/22/21 Guggenheim
Alnylam downgraded to Neutral from Buy at Guggenheim
02/12/21
Fly Intel: Top five analyst downgrades
02/12/21 Barclays
Alnylam price target raised to $196 from $162 at Barclays
02/12/21 Citi
Alnylam downgraded to Neutral from Buy at Citi
ZTS Zoetis
$155.41 /

-1.14 (-0.73%)

SAGE Sage Therapeutics
$85.02 /

+1.45 (+1.74%)

QTNT Quotient
$4.49 /

-0.06 (-1.32%)

QGEN Qiagen
$50.02 /

-0.33 (-0.66%)

PFE Pfizer
$33.49 /

-0.335 (-0.99%)

PACB Pacific Biosciences
$30.57 /

-0.59 (-1.89%)

OTRK Ontrak
$59.13 /

-3.3 (-5.29%)

OCUL Ocular Therapeutix
$18.40 /

+0.27 (+1.49%)

GBT Global Blood Therapeutics
$42.60 /

-0.885 (-2.04%)

EXEL Exelixis
$21.70 /

-0.26 (-1.18%)

DVAX Dynavax
$8.75 /

+0.595 (+7.30%)

CHRS Coherus Biosciences
$16.22 /

+0.97 (+6.36%)

CERS Cerus
$6.14 /

-0.325 (-5.03%)

BLFS BioLife Solutions
$39.29 /

+0.07 (+0.18%)

BIIB Biogen
$272.68 /

-4.95 (-1.78%)

AXSM Axsome Therapeutics
$67.52 /

-1.04 (-1.52%)

ARQT Arcutis Biotherapeutics
$34.11 /

+0.01 (+0.03%)

ALNY Alnylam
$147.94 /

+1.4 (+0.96%)

ACAD Acadia
$49.00 /

+1.605 (+3.39%)

  • 03
    Feb
  • 16
    Dec
  • 11
    Nov
  • 14
    Oct
  • 02
    Oct
  • 11
    Sep
  • 12
    Aug
  • 02
    Jul
  • 22
    May
  • 20
    May
ZTS Zoetis
$155.41 /

-1.14 (-0.73%)

QGEN Qiagen
$50.02 /

-0.33 (-0.66%)

PFE Pfizer
$33.49 /

-0.335 (-0.99%)

PACB Pacific Biosciences
$30.57 /

-0.59 (-1.89%)

BIIB Biogen
$272.68 /

-4.95 (-1.78%)

ALNY Alnylam
$147.94 /

+1.4 (+0.96%)

SAGE Sage Therapeutics
$85.02 /

+1.45 (+1.74%)

QTNT Quotient
$4.49 /

-0.06 (-1.32%)

QGEN Qiagen
$50.02 /

-0.33 (-0.66%)

PFE Pfizer
$33.49 /

-0.335 (-0.99%)

PACB Pacific Biosciences
$30.57 /

-0.59 (-1.89%)

OCUL Ocular Therapeutix
$18.40 /

+0.27 (+1.49%)

GBT Global Blood Therapeutics
$42.60 /

-0.885 (-2.04%)

EXEL Exelixis
$21.70 /

-0.26 (-1.18%)

DVAX Dynavax
$8.75 /

+0.595 (+7.30%)

BLFS BioLife Solutions
$39.29 /

+0.07 (+0.18%)

BIIB Biogen
$272.68 /

-4.95 (-1.78%)

AXSM Axsome Therapeutics
$67.52 /

-1.04 (-1.52%)

ARQT Arcutis Biotherapeutics
$34.11 /

+0.01 (+0.03%)

BIIB Biogen
$272.68 /

-4.95 (-1.78%)

QGEN Qiagen
$50.02 /

-0.33 (-0.66%)

PFE Pfizer
$33.49 /

-0.335 (-0.99%)

PACB Pacific Biosciences
$30.57 /

-0.59 (-1.89%)

OTRK Ontrak
$59.13 /

-3.3 (-5.29%)

DVAX Dynavax
$8.75 /

+0.595 (+7.30%)

BIIB Biogen
$272.68 /

-4.95 (-1.78%)

ARQT Arcutis Biotherapeutics
$34.11 /

+0.01 (+0.03%)

Friday
Hot Stocks
Eli Lilly awarded $210M Army contract for 100,000 doses of antibody therapeutic » 17:27
02/26/21
02/26
17:27
02/26/21
17:27
LLY

Eli Lilly

$204.74 /

+0.835 (+0.41%)

Eli Lilly was awarded a…

Eli Lilly was awarded a $210M firm-fixed-price contract for 100,000 doses of Lilly's combination monoclonal antibody therapeutic treatment. Bids were solicited via the internet with one received. Work locations and funding will be determined with each order, with an estimated completion date of March 31. U.S. Army Contracting Command is the contracting activity.

ShowHide Related Items >><<
LLY Eli Lilly
$204.74 /

+0.835 (+0.41%)

LLY Eli Lilly
$204.74 /

+0.835 (+0.41%)

02/18/21 H.C. Wainwright
Rigel Pharmaceuticals price target raised to $11 from $8 at H.C. Wainwright
02/18/21 Piper Sandler
Rigel share setup 'distinctly positive' after Lilly deal, says Piper Sandler
02/12/21 Cowen
Eli Lilly price target raised to $235 from $195 at Cowen
02/08/21 SVB Leerink
AbCellera price target raised to $52 from $45 at SVB Leerink
LLY Eli Lilly
$204.74 /

+0.835 (+0.41%)

LLY Eli Lilly
$204.74 /

+0.835 (+0.41%)

LLY Eli Lilly
$204.74 /

+0.835 (+0.41%)

LLY Eli Lilly
$204.74 /

+0.835 (+0.41%)

Hot Stocks
Eli Lilly awarded $2.52B Army contract for LY-CoV555, LY-CoV016 » 17:22
02/26/21
02/26
17:22
02/26/21
17:22
LLY

Eli Lilly

$204.74 /

+0.835 (+0.41%)

Eli Lilly was awarded a…

Eli Lilly was awarded a $2.52B firm-fixed-price contract for Eli Lilly's combination monoclonal antibody therapeutic LY-CoV555 and LY-CoV016. Bids were solicited via the internet with one received. Work locations and funding will be determined with each order, with an estimated completion date of November 24. U.S. Army Contracting Command is the contracting activity.

ShowHide Related Items >><<
LLY Eli Lilly
$204.74 /

+0.835 (+0.41%)

LLY Eli Lilly
$204.74 /

+0.835 (+0.41%)

02/18/21 H.C. Wainwright
Rigel Pharmaceuticals price target raised to $11 from $8 at H.C. Wainwright
02/18/21 Piper Sandler
Rigel share setup 'distinctly positive' after Lilly deal, says Piper Sandler
02/12/21 Cowen
Eli Lilly price target raised to $235 from $195 at Cowen
02/08/21 SVB Leerink
AbCellera price target raised to $52 from $45 at SVB Leerink
LLY Eli Lilly
$204.74 /

+0.835 (+0.41%)

LLY Eli Lilly
$204.74 /

+0.835 (+0.41%)

LLY Eli Lilly
$204.74 /

+0.835 (+0.41%)

LLY Eli Lilly
$204.74 /

+0.835 (+0.41%)

Hot Stocks
Eli Lilly: Additional doses of neutralizing antibody therapy purchased by U.S. » 07:02
02/26/21
02/26
07:02
02/26/21
07:02
LLY

Eli Lilly

$203.91 /

-0.735 (-0.36%)

The U.S. government has…

The U.S. government has agreed to purchase a minimum of 100,000 doses of bamlanivimab (LY-CoV555) 700 mg and etesevimab (LY-CoV016) 1400 mg together, Eli Lilly and Company announced. Bamlanivimab and etesevimab together recently received emergency use authorization for the treatment of recently diagnosed, mild to moderate COVID-19 in patients who are at high risk of progressing to severe COVID-19 and/or hospitalization. Additionally, the National Institutes of Health recently updated the COVID-19 Treatment Guidelines to recommend the use of bamlanivimab plus etesevimab for the treatment of outpatients with mild to moderate COVID-19 who are at high risk of clinical progression. The purchase agreement is for $210M and doses will be delivered through March 31, 2021. The U.S. government will have the option to purchase up to an additional 1,100,000 doses through November 25, 2021, under the same terms as the base agreement and subject to agreement from Lilly, product availability and the medical need in the U.S. This purchase adds to the supply of neutralizing antibodies already available for use in the U.S. The government has already committed to purchase a total of 1,450,000 doses of bamlanivimab alone, which includes more than 1 million doses that have been delivered and an agreement to deliver 450,000 additional doses by March 31, 2021. The government has said it will provide neutralizing antibodies at no out-of-pocket cost to patients, although healthcare facilities may charge a fee for the product's administration. Lilly will begin shipping these additional doses immediately.

ShowHide Related Items >><<
LLY Eli Lilly
$203.91 /

-0.735 (-0.36%)

LLY Eli Lilly
$203.91 /

-0.735 (-0.36%)

02/18/21 H.C. Wainwright
Rigel Pharmaceuticals price target raised to $11 from $8 at H.C. Wainwright
02/18/21 Piper Sandler
Rigel share setup 'distinctly positive' after Lilly deal, says Piper Sandler
02/12/21 Cowen
Eli Lilly price target raised to $235 from $195 at Cowen
02/08/21 SVB Leerink
AbCellera price target raised to $52 from $45 at SVB Leerink
LLY Eli Lilly
$203.91 /

-0.735 (-0.36%)

LLY Eli Lilly
$203.91 /

-0.735 (-0.36%)

LLY Eli Lilly
$203.91 /

-0.735 (-0.36%)

LLY Eli Lilly
$203.91 /

-0.735 (-0.36%)

Conference/Events
SVB Leerink to hold a virtual conference » 04:55
02/26/21
02/26
04:55
02/26/21
04:55
ACRS

Aclaris Therapeutics

$21.24 /

+0.52 (+2.51%)

, BBIO

BridgeBio

$65.26 /

-2.3001 (-3.40%)

, HLIO

Helios Technologies

$65.84 /

-1.11 (-1.66%)

, MTCR

Metracrine

$8.57 /

-0.24 (-2.72%)

, SIEN

Sientra

$7.70 /

-0.355 (-4.41%)

, TRVI

Trevi Therapeutics

$2.82 /

-0.07 (-2.42%)

, VCYT

Veracyte

$58.71 /

-3.635 (-5.83%)

, VINC

Vincera Pharma

$19.19 /

-0.92 (-4.57%)

, CTSO

CytoSorbents

$9.70 /

-0.44 (-4.34%)

, CTLT

Catalent

$112.25 /

-2.87 (-2.49%)

, IMRA

Imara

$12.49 /

-0.45 (-3.48%)

, ITOS

iTeos Therapeutics

$41.77 /

+0.77 (+1.88%)

, LLY

Eli Lilly

$203.91 /

-0.735 (-0.36%)

, AUPH

Aurinia Pharmaceuticals

$14.59 /

+0.015 (+0.10%)

, AVXL

Anavex

$13.01 /

+0.65 (+5.26%)

, DRIO

DarioHealth

$27.17 /

-2.22 (-7.55%)

, ENTA

Enanta

$50.58 /

-1.1548 (-2.23%)

, EQ

Equillium

$7.65 /

-0.22 (-2.80%)

, EXEL

Exelixis

$21.96 /

-0.73 (-3.22%)

, SDGR

Schrodinger

$104.43 /

-6.46 (-5.83%)

10th Annual Global…

10th Annual Global Healthcare Virtual Conference will be held on February 22-26.

ShowHide Related Items >><<
VINC Vincera Pharma
$19.19 /

-0.92 (-4.57%)

VCYT Veracyte
$58.71 /

-3.635 (-5.83%)

TRVI Trevi Therapeutics
$2.82 /

-0.07 (-2.42%)

SIEN Sientra
$7.70 /

-0.355 (-4.41%)

SDGR Schrodinger
$104.43 /

-6.46 (-5.83%)

MTCR Metracrine
$8.57 /

-0.24 (-2.72%)

LLY Eli Lilly
$203.91 /

-0.735 (-0.36%)

ITOS iTeos Therapeutics
$41.77 /

+0.77 (+1.88%)

IMRA Imara
$12.49 /

-0.45 (-3.48%)

HLIO Helios Technologies
$65.84 /

-1.11 (-1.66%)

EXEL Exelixis
$21.96 /

-0.73 (-3.22%)

EQ Equillium
$7.65 /

-0.22 (-2.80%)

ENTA Enanta
$50.58 /

-1.1548 (-2.23%)

DRIO DarioHealth
$27.17 /

-2.22 (-7.55%)

CTSO CytoSorbents
$9.70 /

-0.44 (-4.34%)

CTLT Catalent
$112.25 /

-2.87 (-2.49%)

BBIO BridgeBio
$65.26 /

-2.3001 (-3.40%)

AVXL Anavex
$13.01 /

+0.65 (+5.26%)

AUPH Aurinia Pharmaceuticals
$14.59 /

+0.015 (+0.10%)

ACRS Aclaris Therapeutics
$21.24 /

+0.52 (+2.51%)

ACRS Aclaris Therapeutics
$21.24 /

+0.52 (+2.51%)

02/02/21 Cantor Fitzgerald
Aclaris Therapeutics price target raised to $30 from $15 at Cantor Fitzgerald
01/19/21 William Blair
Aclaris has potential in range of 'blockbuster indications,' says William Blair
BBIO BridgeBio
$65.26 /

-2.3001 (-3.40%)

02/22/21 JPMorgan
BridgeBio reinstated with an Overweight at JPMorgan
02/09/21
Fly Intel: Top five analyst initiations
02/09/21 Goldman Sachs
BridgeBio reinstated with a Buy at Goldman Sachs
01/11/21 H.C. Wainwright
BridgeBio price target raised to $87 from $64 at H.C. Wainwright
HLIO Helios Technologies
$65.84 /

-1.11 (-1.66%)

10/12/20 Baird
Helios Technologies upgraded to Outperform from Neutral at Baird
05/29/20 Morgan Stanley
Morgan Stanley upgrades Helios to Equal Weight following underperformance
05/29/20 Morgan Stanley
Helios Technologies upgraded to Equal Weight from Underweight at Morgan Stanley
03/27/20 Truist
Helios Technologies price target lowered to $36 from $45 at SunTrust
MTCR Metracrine
$8.57 /

-0.24 (-2.72%)

10/12/20 Canaccord
Metracrine initiated with a Buy at Canaccord
10/12/20 Jefferies
Metracrine initiated with a Buy at Jefferies
10/12/20 RBC Capital
Metracrine initiated with an Outperform at RBC Capital
SIEN Sientra
$7.70 /

-0.355 (-4.41%)

02/05/21 Canaccord
Sientra price target raised to $8 from $6 at Canaccord
10/08/20 Stifel
Stifel sees upside potential for Sientra after survey of aesthetics doctors
06/11/20 Maxim
Sientra price target raised to $8 from $5 at Maxim
03/12/20 Craig-Hallum
Sientra price target lowered to $9 from $14 at Craig-Hallum
TRVI Trevi Therapeutics
$2.82 /

-0.07 (-2.42%)

07/13/20 Stifel
Trevi Therapeutics price target lowered to $10 from $14 at Stifel
VCYT Veracyte
$58.71 /

-3.635 (-5.83%)

02/18/21 Needham
Veracyte assumed with a Buy at Needham
02/08/21 SVB Leerink
Veracyte price target raised to $83 from $40 at SVB Leerink
01/27/21 Truist
Veracyte initiated with a Buy at Truist
12/17/20 Lake Street
Veracyte price target raised to $60 from $40 at Lake Street
VINC Vincera Pharma
$19.19 /

-0.92 (-4.57%)

01/06/21 Chardan
Vincera Pharma initiated with a Buy at Chardan
CTSO CytoSorbents
$9.70 /

-0.44 (-4.34%)

01/04/21 B. Riley Securities
CytoSorbents price target raised to $17 from $16 at B. Riley Securities
09/01/20 SVB Leerink
CytoSorbents initiated with an Outperform at SVB Leerink
08/25/20 B. Riley Securities
CytoSorbents 29% pullback from highs a buying opportunity, says B. Riley FBR
06/02/20 B. Riley Securities
CytoSorbents gaining relevance as COVID-19 treatment, says B. Riley FBR
CTLT Catalent
$112.25 /

-2.87 (-2.49%)

02/03/21 UBS
Catalent price target raised to $135 from $115 at UBS
02/03/21 RBC Capital
Catalent price target raised to $137 from $125 at RBC Capital
01/08/21 JPMorgan
Catalent price target raised to $130 from $110 at JPMorgan
01/04/21 Stephens
Brinker, LiveRamp and Vonage among 2021 best ideas at Stephens
IMRA Imara
$12.49 /

-0.45 (-3.48%)

01/06/21 SVB Leerink
Imara selloff a potential buying opportunity, says SVB Leerink
08/17/20
Fly Intel: Top five analyst upgrades
08/17/20 Citi
Imara upgraded to Buy from Neutral at Citi
06/30/20 Citi
Imara downgraded to Neutral from Buy at Citi
ITOS iTeos Therapeutics
$41.77 /

+0.77 (+1.88%)

10/07/20 Baird
iTeos Therapeutics initiated with an Outperform at Baird
09/18/20 Piper Sandler
Piper Sandler lays out next potential takeover targets in oncology
09/01/20 Piper Sandler
iTeos Therapeutics heading for 'catalyst rich stretch', says Piper Sandler
08/18/20 SVB Leerink
SVB Leerink bullish on iTeos Therapeutics, initiates with an Outperform
LLY Eli Lilly
$203.91 /

-0.735 (-0.36%)

02/18/21 H.C. Wainwright
Rigel Pharmaceuticals price target raised to $11 from $8 at H.C. Wainwright
02/18/21 Piper Sandler
Rigel share setup 'distinctly positive' after Lilly deal, says Piper Sandler
02/12/21 Cowen
Eli Lilly price target raised to $235 from $195 at Cowen
02/08/21 SVB Leerink
AbCellera price target raised to $52 from $45 at SVB Leerink
AUPH Aurinia Pharmaceuticals
$14.59 /

+0.015 (+0.10%)

01/26/21 RBC Capital
Aurinia Pharmaceuticals price target raised to $28 from $20 at RBC Capital
01/26/21 Cantor Fitzgerald
Aurinia Pharmaceuticals price target raised to $34 from $27 at Cantor Fitzgerald
01/25/21 Oppenheimer
Aurinia Pharmaceuticals price target raised to $28 from $20 at Oppenheimer
01/25/21 H.C. Wainwright
Aurinia Pharmaceuticals price target raised to $35 from $30 at H.C. Wainwright
AVXL Anavex
$13.01 /

+0.65 (+5.26%)

02/24/21 Cantor Fitzgerald
Anavex price target raised to $25 from $10 at Cantor Fitzgerald
02/23/21 Cantor Fitzgerald
Anavex price target raised to $25 from $10 at Cantor Fitzgerald
12/29/20 Cantor Fitzgerald
Anavex cash position to fund operations into 2022, says Cantor Fitzgerald
12/16/20 H.C. Wainwright
Anavex price target raised to $17 from $14 at H.C. Wainwright
DRIO DarioHealth
$27.17 /

-2.22 (-7.55%)

02/01/21 Alliance Global Partners
DarioHealth downgraded to Neutral from Buy at Alliance Global Partners
08/17/20 Aegis
DarioHealth initiated with a Buy at Aegis
08/13/20 Craig-Hallum
DarioHealth price target raised to $17 from $8 at Craig-Hallum
06/22/20 ThinkEquity
DarioHealth initiated with a Buy at ThinkEquity
ENTA Enanta
$50.58 /

-1.1548 (-2.23%)

02/09/21 RBC Capital
Enanta price target raised to $53 from $47 at RBC Capital
01/29/21 JPMorgan
Enanta upgraded to Neutral with $55 target at JPMorgan
01/29/21 JPMorgan
Enanta upgraded to Neutral from Underweight at JPMorgan
01/08/21 Piper Sandler
Enanta remains 'significantly undervalued,' says Piper Sandler
EQ Equillium
$7.65 /

-0.22 (-2.80%)

11/30/20 H.C. Wainwright
Equillium price target lowered to $12 from $22 at H.C. Wainwright
07/14/20 H.C. Wainwright
Equillium price target raised to $24 from $14 at H.C. Wainwright
07/10/20 Stifel
Equillium transferred with Buy rating, $10 target at Stifel
EXEL Exelixis
$21.96 /

-0.73 (-3.22%)

02/15/21 Piper Sandler
Exelixis price target raised to $36 from $33 at Piper Sandler
01/25/21 Piper Sandler
Piper says Exelixis could have 'blockbuster opportunity' with XL102
01/22/21 Piper Sandler
Exelixis combo approval came a month ahead of PDUFA, says Piper Sandler
01/20/21 William Blair
Exelixis selloff on competitive concerns an 'overreaction,' says William Blair
SDGR Schrodinger
$104.43 /

-6.46 (-5.83%)

01/25/21 BMO Capital
Schrodinger price target raised to $117 from $97 at BMO Capital
11/23/20 BofA
BofA upgrades Schrodinger to Buy after 'major' collaboration announcement
11/23/20 BofA
Schrodinger upgraded to Buy from Neutral at BofA
10/12/20 Jefferies
Schrodinger upgraded to Buy from Hold at Jefferies
VCYT Veracyte
$58.71 /

-3.635 (-5.83%)

SIEN Sientra
$7.70 /

-0.355 (-4.41%)

SDGR Schrodinger
$104.43 /

-6.46 (-5.83%)

MTCR Metracrine
$8.57 /

-0.24 (-2.72%)

LLY Eli Lilly
$203.91 /

-0.735 (-0.36%)

ITOS iTeos Therapeutics
$41.77 /

+0.77 (+1.88%)

IMRA Imara
$12.49 /

-0.45 (-3.48%)

HLIO Helios Technologies
$65.84 /

-1.11 (-1.66%)

EXEL Exelixis
$21.96 /

-0.73 (-3.22%)

EQ Equillium
$7.65 /

-0.22 (-2.80%)

ENTA Enanta
$50.58 /

-1.1548 (-2.23%)

DRIO DarioHealth
$27.17 /

-2.22 (-7.55%)

CTSO CytoSorbents
$9.70 /

-0.44 (-4.34%)

CTLT Catalent
$112.25 /

-2.87 (-2.49%)

BBIO BridgeBio
$65.26 /

-2.3001 (-3.40%)

AVXL Anavex
$13.01 /

+0.65 (+5.26%)

AUPH Aurinia Pharmaceuticals
$14.59 /

+0.015 (+0.10%)

ACRS Aclaris Therapeutics
$21.24 /

+0.52 (+2.51%)

  • 12
    Feb
  • 09
    Feb
  • 05
    Feb
  • 20
    Jan
  • 23
    Nov
  • 16
    Sep
  • 14
    Aug
  • 13
    Aug
  • 05
    Aug
  • 23
    Jul
  • 22
    Jul
  • 24
    Jul
  • 11
    Jun
  • 29
    May
  • 12
    Mar
LLY Eli Lilly
$203.91 /

-0.735 (-0.36%)

BBIO BridgeBio
$65.26 /

-2.3001 (-3.40%)

AUPH Aurinia Pharmaceuticals
$14.59 /

+0.015 (+0.10%)

VINC Vincera Pharma
$19.19 /

-0.92 (-4.57%)

VCYT Veracyte
$58.71 /

-3.635 (-5.83%)

SIEN Sientra
$7.70 /

-0.355 (-4.41%)

SDGR Schrodinger
$104.43 /

-6.46 (-5.83%)

MTCR Metracrine
$8.57 /

-0.24 (-2.72%)

LLY Eli Lilly
$203.91 /

-0.735 (-0.36%)

IMRA Imara
$12.49 /

-0.45 (-3.48%)

EXEL Exelixis
$21.96 /

-0.73 (-3.22%)

EQ Equillium
$7.65 /

-0.22 (-2.80%)

ENTA Enanta
$50.58 /

-1.1548 (-2.23%)

CTLT Catalent
$112.25 /

-2.87 (-2.49%)

BBIO BridgeBio
$65.26 /

-2.3001 (-3.40%)

AVXL Anavex
$13.01 /

+0.65 (+5.26%)

AUPH Aurinia Pharmaceuticals
$14.59 /

+0.015 (+0.10%)

ACRS Aclaris Therapeutics
$21.24 /

+0.52 (+2.51%)

SDGR Schrodinger
$104.43 /

-6.46 (-5.83%)

LLY Eli Lilly
$203.91 /

-0.735 (-0.36%)

AUPH Aurinia Pharmaceuticals
$14.59 /

+0.015 (+0.10%)

Thursday
Hot Stocks
AbbVie's Allergan submits NDA to FDA for investigational AGN-190584 » 08:04
02/25/21
02/25
08:04
02/25/21
08:04
ABBV

AbbVie

$108.68 /

+2.42 (+2.28%)

Allergan, an AbbVie…

Allergan, an AbbVie company, announced that it has submitted a New Drug Application to the U.S. FDA for investigational AGN-190584 (pilocarpine 1.25%) ophthalmic solution for the treatment of presbyopia. The FDA is expected to act on the NDA by the end of 2021.

ShowHide Related Items >><<
ABBV AbbVie
$108.68 /

+2.42 (+2.28%)

ABBV AbbVie
$108.68 /

+2.42 (+2.28%)

02/24/21 Truist
Evolus downgraded to Hold from Buy at Truist
02/19/21 Stifel
Stifel raises Evolus price target to $25, calls settlement a 'win for all'
02/04/21 SVB Leerink
AbbVie price target raised to $140 from $128 at SVB Leerink
02/04/21
AbbVie price target raised to $135 from $129 at RBC Capital
ABBV AbbVie
$108.68 /

+2.42 (+2.28%)

ABBV AbbVie
$108.68 /

+2.42 (+2.28%)

ABBV AbbVie
$108.68 /

+2.42 (+2.28%)

ABBV AbbVie
$108.68 /

+2.42 (+2.28%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.